Immunology Sponsored by Beckman Coulter
Will SARS-CoV-2 become an endemic seasonal coronavirus?
U.K. virologists have reviewed over 40 studies on SARS-CoV-2 immunity and discussed how this current knowledge about immune responses can inform virus control strategies. They shared their analysis in an article published in the Journal of General Virology on May 20.  Discuss
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.  Discuss
Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating the development of an effective vaccine to SARS-CoV-2 infection. The results of the study were published in Immunity on May 3.  Discuss
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents the SARS-CoV-2 virus from infecting cultured cells. Authored by a team of researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed, the report was published in Nature Communications on May 4.  Discuss
Cytokine storm may cause T-cell exhaustion in COVID-19 cases
Cytokine storms may impact the severity of COVID-19 cases by lowering T-cell populations, according to a study published in Frontiers in Immunology on May 1.  Discuss
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene therapy, according to a new review article published April 24 in Frontiers in Microbiology.  Discuss
Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly reduce the discovery time for possible new antibody-based therapies. The approach, published in Nature Communications on April 14, shows how protein fragments can be screened for susceptibility to aggregation in early drug discovery.  Discuss
SARS-CoV-2 vaccine utilizing microneedle arrays appears in the literature
Within four weeks of the SARS-CoV-2 spike sequence becoming available, researchers from the University of Pittsburgh School of Medicine developed immunogens for a potential COVID-19 vaccine. The vaccine is delivered through a fingertip-sized patch, and it produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus, according to the April 2 EBioMedicine publication.  Discuss
Chemists develop method to identify protein neighbors
A new technology called µMap uses photocatalysts, molecules that spur a chemical reaction when activated by light, to identify spatial relationships of cell surface proteins. The results are described by scientists from Princeton University and Merck in the March 6 edition of Science.  Discuss
Breakthrough in coronavirus research provides map for vaccines
Critical research reveals the 3D atomic-scale map of the spike protein of the 2019 novel coronavirus (2019-nCoV), which is responsible for infecting humans. This breakthrough will aid in the development of vaccines and antiviral drugs to combat the spread of the virus. The research was published in Science on February 19.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter